{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T15:29:59Z","timestamp":1744298999330},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.dld.2023.12.018","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T14:18:33Z","timestamp":1705414713000},"page":"1375-1381","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients"],"prefix":"10.1016","volume":"56","author":[{"given":"Emmanuelle","family":"Samalin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Mazard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Assenat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Rouyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"de la Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosine","family":"Guimbaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Portales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ychou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Adenis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Fiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyne","family":"Lopez-Crapez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Thezenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dld.2023.12.018_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.dld.2023.12.018_bib0002","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.dld.2019.05.035","article-title":"Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)","volume":"51","author":"Phelip","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.dld.2023.12.018_bib0003","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"17_suppl","key":"10.1016\/j.dld.2023.12.018_bib0004","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1","article-title":"Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial","volume":"40","author":"Yoshino","year":"2022","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.dld.2023.12.018_bib0005","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1200\/JCO.2022.40.16_suppl.3504","article-title":"STRATEGIC-1: multi-line therapy trial in unresectable wild-type KRAS\/NRAS\/BRAF metastatic colorectal cancer\u2013a GERCOR-PRODIGE randomized open-label phase III study","volume":"40","author":"Chibaudel","year":"2022","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.dld.2023.12.018_bib0006","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2022.40.16_suppl.3503","article-title":"Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI\/PANI) for first-line treatment of patients (pts) with RAS\/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): the IMPROVE study","volume":"40","author":"Avallone","year":"2022","journal-title":"JCO"},{"issue":"17_suppl","key":"10.1016\/j.dld.2023.12.018_bib0007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3506","article-title":"FOLFOXIRI + bevacizumab versus FOLFOX\/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and\/or RAS\/BRAFV600E-mutated primary tumor: phase III CAIRO5 study of the Dutch Colorectal Cancer Group","volume":"40","author":"Punt","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.dld.2023.12.018_bib0008","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.dld.2023.12.018_bib0009","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.22.01420","article-title":"FOLFOXIRI plus cetuximab or bevacizumab as first-line treatment of BRAFV600E-mutant metastatic colorectal cancer: the randomized phase II FIRE-4.5 (AIO KRK0116) study","volume":"41","author":"Stintzing","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2023.12.018_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102301","article-title":"Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: current evidence, advances, and future perspectives","volume":"102","author":"Folprecht","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.dld.2023.12.018_bib0011","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1634\/theoncologist.2020-0563","article-title":"Modified FOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS\/BRAF wild-type unresectable liver metastases colorectal cancer: the FOCULM multicenter phase II trial","volume":"26","author":"Hu","year":"2021","journal-title":"Oncologist"},{"issue":"15_suppl","key":"10.1016\/j.dld.2023.12.018_bib0012","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1200\/JCO.2020.38.15_suppl.4024","article-title":"Cetuximab\/irinotecan\/5-FU +\/-oxaliplatin or FOLFOXIRI +\/- bevacizumab in patients with colorectal cancer and nonresectable liver metastases (AIO CELIM2-study)","volume":"38","author":"Folprecht","year":"2020","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.dld.2023.12.018_bib0013","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaoncol.2017.5314","article-title":"Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a randomized phase 2 clinical trial","volume":"4","author":"Cremolini","year":"2018","journal-title":"JAMA Oncol"},{"issue":"25","key":"10.1016\/j.dld.2023.12.018_bib0014","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1200\/JCO.22.00839","volume":"40","author":"Rossini","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.dld.2023.12.018_bib0015","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41416-021-01644-y","article-title":"Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial","volume":"126","author":"Ychou","year":"2022","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.dld.2023.12.018_bib0016","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1634\/theoncologist.2011-0141","article-title":"Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial","volume":"16","author":"Assenat","year":"2011","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.dld.2023.12.018_bib0017","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/bcp.14472","article-title":"Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort","volume":"87","author":"Rouyer","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"31","key":"10.1016\/j.dld.2023.12.018_bib0018","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.dld.2023.12.018_bib0019","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.dld.2023.12.018_bib0020","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.dld.2023.12.018_bib0021","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.dld.2023.12.018_bib0022","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.19.01340","article-title":"FOLFOXIRI plus panitumumab as first-line treatment of RAS Wild-Type Metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109)","volume":"37","author":"Modest","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.dld.2023.12.018_bib0023","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2023.12.018_bib0024","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","article-title":"The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials","volume":"70","author":"Holch","year":"2017","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.dld.2023.12.018_bib0025","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/bjc.2015.173","article-title":"Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer","volume":"112","author":"Rowland","year":"2015","journal-title":"Br J Cancer"},{"issue":"17","key":"10.1016\/j.dld.2023.12.018_bib0026","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.dld.2023.12.018_bib0027","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2023.12.018_bib0028","doi-asserted-by":"crossref","first-page":"viii150","DOI":"10.1093\/annonc\/mdy281.001","article-title":"1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: a randomized phase II VOLFI trial of the AIO (KRK-0109)","volume":"29","author":"Geissler","year":"2018","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.dld.2023.12.018_bib0029","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1245\/s10434-013-3217-x","article-title":"A randomized phase ii trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial","volume":"20","author":"Ychou","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2023.12.018_bib0030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2016.10.028","article-title":"Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: a pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest","volume":"73","author":"Cremolini","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.dld.2023.12.018_bib0031","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s10147-017-1228-5","article-title":"Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced\/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study","volume":"23","author":"Satake","year":"2018","journal-title":"Int J Clin Oncol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582400001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582400001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T19:43:08Z","timestamp":1729021388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086582400001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S159086582400001X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2023.12.018","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2023.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}